S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:PBYI

Puma Biotechnology Stock Forecast, Price & News

$10.78
-0.22 (-2.00 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.65
Now: $10.78
$11.29
50-Day Range
$10.13
MA: $11.13
$12.13
52-Week Range
$5.50
Now: $10.78
$15.00
Volume308,834 shs
Average Volume367,456 shs
Market Capitalization$428.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology logo

MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

496th out of 1,480 stocks

Pharmaceutical Preparations Industry

256th out of 612 stocks

Analyst Opinion: 2.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Employees269

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$272.30 million
Book Value$0.45 per share

Profitability

Net Income$-75,600,000.00

Miscellaneous

Market Cap$428.63 million
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$10.78
-0.22 (-2.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

How has Puma Biotechnology's stock been impacted by Coronavirus (COVID-19)?

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PBYI stock has increased by 16.3% and is now trading at $10.78.
View which stocks have been most impacted by COVID-19
.

Is Puma Biotechnology a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Puma Biotechnology?

Wall Street analysts have given Puma Biotechnology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Puma Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Puma Biotechnology
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.40. The biopharmaceutical company earned $50.80 million during the quarter, compared to the consensus estimate of $52.97 million. Puma Biotechnology had a negative return on equity of 246.80% and a negative net margin of 17.25%. Puma Biotechnology's revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.12) EPS.
View Puma Biotechnology's earnings history
.

What price target have analysts set for PBYI?

7 brokers have issued 1-year price targets for Puma Biotechnology's stock. Their forecasts range from $9.00 to $17.00. On average, they anticipate Puma Biotechnology's share price to reach $13.14 in the next year. This suggests a possible upside of 21.9% from the stock's current price.
View analysts' price targets for Puma Biotechnology
or view Wall Street analyst' top-rated stocks.

Who are some of Puma Biotechnology's key competitors?

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 50, Pay $1.3M)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 51, Pay $665.8k)
  • Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 63, Pay $720.3k)
  • Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management (Age 55, Pay $523.83k)
  • Mr. Mariann Ohanesian, Sr. Director of Investor Relations
  • Charon Spencer Sr., VP of HR
  • Mr. Jeffrey Jerome Ludwig, Chief Commercial Officer (Age 54)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.03%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology
.

Which major investors are buying Puma Biotechnology stock?

PBYI stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for Puma Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $10.78.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $428.63 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 269 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is www.pumabiotechnology.com.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.